KLRK1 and cancer: Conventional drugs like temozolomide, doxorubicin, and 5-fluorouracyl can sensitize cancer cells from solid tumors to Vγ9Vδ2 T cells by inducing the upregulation of Fas, TRAIL-R1, and TRAL-R2 that are recognized by Vγ9Vδ2 T cells via NKG2D and TRAIL (126, 127).